Author: scott forrest

Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.  The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide the majority of national coverage across the Canadian market and position […]

Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial traction in the United States, and expanding global adoption of Remplir™.

Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.